哈萨克斯坦将建造203M 生物制药综合体, 生产58种药品, 创造180个就业机会。 Kazakhstan to build $203M biopharmaceutical complex producing 58 medicines, creating 180 jobs.

哈萨克斯坦将在阿拉托特别经济区建造一个全周期生物制药综合体,投资额超过1030亿坚戈(2.03亿美元),生产58种药品,包括肿瘤、自体免疫和罕见疾病的活性成分。 Kazakhstan will build a full-cycle biopharmaceutical complex in the Alatau Special Economic Zone with over 103 billion tenge ($203 million) in investment, producing 58 medicines including active ingredients for oncology, autoimmune, and rare diseases. 该设施由奥尔扎斯·贝克泰诺夫总理批准,将生产27种国际非专利药品,创造180多个就业机会,支持进口替代,以加强家庭保健。 The facility, approved by Prime Minister Olzhas Bektenov, will manufacture 27 international nonproprietary drugs, create over 180 jobs, and support import substitution to strengthen domestic healthcare. 有些产品可能出口到EAEU、独联体和中东国家,推动哈萨克斯坦成为区域制药中心的目标。 Some products may be exported to EAEU, CIS, and Middle Eastern countries, advancing Kazakhstan’s goal of becoming a regional pharmaceutical hub.